Cutera, Inc. (NASDAQ:CUTR)‘s stock had its “buy” rating reaffirmed by analysts at Gabelli in a note issued to investors on Wednesday.

Other research analysts have also recently issued research reports about the company. BidaskClub cut Cutera from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Maxim Group reiterated a “buy” rating and issued a $33.00 target price (up previously from $27.00) on shares of Cutera in a report on Thursday, July 13th. Roth Capital initiated coverage on Cutera in a report on Monday, June 26th. They issued a “buy” rating and a $32.00 target price on the stock. Zacks Investment Research upgraded Cutera from a “sell” rating to a “buy” rating and set a $28.00 target price on the stock in a report on Tuesday, June 20th. Finally, Sidoti reiterated a “buy” rating and issued a $30.00 target price (up previously from $27.00) on shares of Cutera in a report on Saturday, June 3rd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $33.25.

Shares of Cutera (NASDAQ CUTR) traded down 0.233% during trading on Wednesday, hitting $32.175. The stock had a trading volume of 75,634 shares. The stock’s 50 day moving average is $26.06 and its 200-day moving average is $21.93. Cutera has a 12-month low of $10.54 and a 12-month high of $32.70. The company has a market cap of $445.88 million, a PE ratio of 123.276 and a beta of 0.60.

Cutera (NASDAQ:CUTR) last issued its earnings results on Monday, August 7th. The medical device company reported $0.13 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.10. Cutera had a return on equity of 11.77% and a net margin of 5.07%. The firm had revenue of $36.40 million for the quarter, compared to analysts’ expectations of $32.08 million. During the same quarter last year, the firm earned $0.07 earnings per share. The firm’s revenue for the quarter was up 32.4% compared to the same quarter last year. Analysts forecast that Cutera will post $0.47 earnings per share for the current year.

Cutera declared that its Board of Directors has approved a share buyback program on Monday, August 7th that authorizes the company to buyback $25.00 million in outstanding shares. This buyback authorization authorizes the medical device company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board of directors believes its stock is undervalued.

WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/09/cutera-inc-nasdaqcutr-given-buy-rating-at-gabelli.html.

In related news, Director David A. Gollnick sold 10,000 shares of the business’s stock in a transaction dated Monday, June 26th. The stock was sold at an average price of $25.08, for a total value of $250,800.00. Following the transaction, the director now owns 26,641 shares in the company, valued at $668,156.28. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Ronald J. Santilli sold 3,857 shares of the business’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $22.95, for a total value of $88,518.15. Following the completion of the transaction, the chief financial officer now owns 88,321 shares in the company, valued at approximately $2,026,966.95. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 64,563 shares of company stock worth $1,485,360. 3.30% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Scout Investments Inc. acquired a new position in Cutera during the second quarter valued at approximately $1,454,000. Federated Investors Inc. PA boosted its position in Cutera by 2.5% in the second quarter. Federated Investors Inc. PA now owns 58,415 shares of the medical device company’s stock valued at $1,513,000 after buying an additional 1,427 shares during the period. Cadence Capital Management LLC acquired a new position in Cutera during the second quarter valued at approximately $1,249,000. DE Burlo Group Inc. acquired a new position in Cutera during the second quarter valued at approximately $1,212,000. Finally, Gamco Investors INC. ET AL boosted its position in Cutera by 3.7% in the second quarter. Gamco Investors INC. ET AL now owns 576,363 shares of the medical device company’s stock valued at $14,928,000 after buying an additional 20,363 shares during the period. Institutional investors and hedge funds own 82.87% of the company’s stock.

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Receive News & Stock Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related stocks with our FREE daily email newsletter.